Discontinuation report ENHERTU
| Report ID | 257632 |
| Drug Identification Number | 02514400 |
| Brand name | ENHERTU |
| Common or Proper name | Common or Proper name |
| Company Name | ASTRAZENECA CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | TRASTUZUMAB DERUXTECAN |
| Strength(s) | 100MG |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS |
| Packaging size | Packaging size |
| ATC code | L01FD |
| ATC description | |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | 2022-02-03 |
| Actual discontinuation date | |
| Remaining supply date | |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Please contact AstraZeneca Canada Medical Information for any specific questions at 1-800-668-6000 (EN) or 1-800-461-3787 (FR) or by email: [email protected]. Veuillez contacter le Service d'information médicale d'AstraZeneca Canada pour toute question spécifique au 1-800-668-6000 (EN) ou au 1-800-461-3787 (FR) ou par courriel : [email protected]. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2025-10-31 | French | Compare |
| v1 | 2025-10-31 | English | Compare |
Showing 1 to 2 of 2